{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T23:37:21Z","timestamp":1773445041278,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.ejso.2024.108540","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T18:14:44Z","timestamp":1720635284000},"page":"108540","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["The role of extensive lymph node dissection in the new grading system for lung adenocarcinoma"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0284-3570","authenticated-orcid":false,"given":"Chia","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2250-0797","authenticated-orcid":false,"given":"Lei-Chi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jui-Fen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ko-Han","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Chen","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po-Kuei","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3206-2869","authenticated-orcid":false,"given":"Chien-Sheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Cheng","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han-Shui","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ejso.2024.108540_bib1","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1097\/JTO.0000000000000663","article-title":"Introduction to the 2015 world Health organization classification of tumors of the lung, pleura, thymus, and heart","volume":"10","author":"Travis","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejso.2024.108540_bib2","series-title":"Proposed novel grading system for stage I invasive lung adenocarcinoma and a comparison with the 2020 IASLC grading system","author":"Wang","year":"2024"},{"issue":"10","key":"10.1016\/j.ejso.2024.108540_bib3","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.jtho.2020.06.001","article-title":"A grading system for invasive pulmonary adenocarcinoma: a proposal from the international association for the study of lung cancer pathology committee","volume":"15","author":"Moreira","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2024.108540_bib4","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jtho.2019.10.019","article-title":"The IASLC lung cancer staging Project: analysis of resection margin status and proposals for residual tumor descriptors for non-small cell lung cancer","volume":"15","author":"Edwards","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2024.108540_bib5","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00428-017-2276-y","article-title":"Eighth Edition of the UICC Classification of Malignant Tumours: an overview of the changes in the pathological TNM classification criteria-What has changed and why?","volume":"472","author":"Bertero","year":"2018","journal-title":"Virchows Arch"},{"issue":"2","key":"10.1016\/j.ejso.2024.108540_bib6","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.jtcvs.2017.03.085","article-title":"Survival impact of postoperative therapy modalities according to margin status in non-small cell lung cancer patients in the United States","volume":"154","author":"Smeltzer","year":"2017","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"9","key":"10.1016\/j.ejso.2024.108540_bib7","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1002\/cncr.10492","article-title":"TNM residual tumor classification revisited","volume":"94","author":"Wittekind","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2024.108540_bib8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.lungcan.2022.07.019","article-title":"Investigation of the non-small cell lung cancer patients with uncertain resection: a population-based study","volume":"171","author":"Wang","year":"2022","journal-title":"Lung Cancer"},{"issue":"7","key":"10.1016\/j.ejso.2024.108540_bib9","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.jtho.2022.03.015","article-title":"Reclassifying the international association for the study of lung cancer residual tumor classification according to the extent of nodal dissection for NSCLC: one size does not fit all","volume":"17","author":"Lee","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2024.108540_bib10","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.athoracsur.2021.07.087","article-title":"Prognostic value of uncertain resection for overall survival in non-small cell lung cancer","volume":"114","author":"Kadomatsu","year":"2022","journal-title":"Ann Thorac Surg"},{"issue":"1","key":"10.1016\/j.ejso.2024.108540_bib11","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2017.2993","article-title":"Association of pathologic nodal staging quality with survival among patients with non-small cell lung cancer after resection with curative intent","volume":"4","author":"Smeltzer","year":"2018","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2024.108540_bib12","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jtcvs.2010.11.008","article-title":"Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial","volume":"141","author":"Darling","year":"2011","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"10","key":"10.1016\/j.ejso.2024.108540_bib13","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.jtho.2021.04.008","article-title":"Validation study of the international association for the study of lung cancer histologic grading system of invasive lung adenocarcinoma","volume":"16","author":"Rokutan-Kurata","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2024.108540_bib14","first-page":"407","article-title":"[Updated interpretation of the NCCN clinical practice guidelines (version 3. 2023) for non-small cell lung cancer]","volume":"26","author":"Zhu","year":"2023","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"10.1016\/j.ejso.2024.108540_bib15","first-page":"101","article-title":"Stage as the sole \"biomarker\" for adjuvant pembrolizumab in resected stage IB to IIIA NSCLC without considerations for PD-L1 expression level, ALK\/EGFR mutational status, and prior adjuvant chemotherapy per FDA approval indications of PEARLS\/Keynote-091?","volume":"14","author":"Nagasaka","year":"2023","journal-title":"Lung Cancer"},{"issue":"10","key":"10.1016\/j.ejso.2024.108540_bib16","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial","volume":"23","author":"O'Brien","year":"2022","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2024.108540_bib17","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1200\/JCO.20.01820","article-title":"Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC: final overall survival analysis of CTONG1104 phase III trial","volume":"39","author":"Zhong","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2024.108540_bib18","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.lungcan.2020.09.027","article-title":"Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II-IIIA (N1-N2) EGFR-mutant non-small-cell lung cancer: results from the ADJUVANT (CTONG1104) study","volume":"150","author":"Zeng","year":"2020","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.ejso.2024.108540_bib19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1470-2045(17)30729-5","article-title":"Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT\/CTONG1104): a randomised, open-label, phase 3 study","volume":"19","author":"Zhong","year":"2018","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2024.108540_bib20","article-title":"Adjuvant osimertinib in patients with stage IB to IIIA EGFR mutation-positive NSCLC after complete tumor resection: ADAURA China subgroup analysis","volume":"5","author":"Wang","year":"2024","journal-title":"JTO Clin Res Rep"},{"issue":"4","key":"10.1016\/j.ejso.2024.108540_bib21","doi-asserted-by":"crossref","first-page":"e533","DOI":"10.1016\/j.cllc.2018.04.004","article-title":"ADAURA: phase III, double-blind, randomized study of osimertinib versus placebo in EGFR mutation-positive early-stage NSCLC after complete surgical resection","volume":"19","author":"Wu","year":"2018","journal-title":"Clin Lung Cancer"},{"issue":"6","key":"10.1016\/j.ejso.2024.108540_bib23","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/his.14301","article-title":"Inclusion of multiple high-risk histopathological criteria improves the prediction of adjuvant chemotherapy efficacy in lung adenocarcinoma","volume":"78","author":"Sereno","year":"2021","journal-title":"Histopathology"},{"issue":"22","key":"10.1016\/j.ejso.2024.108540_bib22","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1200\/JCO.2013.50.1049","article-title":"Predictive value of the international association for the study of lung cancer\/American Thoracic Society\/European Respiratory Society classification of lung adenocarcinoma in tumor recurrence and patient survival","volume":"32","author":"Hung","year":"2014","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejso.2024.108540_bib26","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/j.jtho.2021.07.006","article-title":"Validation of the novel international association for the study of lung cancer grading system for invasive pulmonary adenocarcinoma and association with common driver mutations","volume":"16","author":"Deng","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejso.2024.108540_bib24","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.lungcan.2023.02.010","article-title":"Thoracic Alliance of Rising Star, Frozen sections accurately predict the IASLC proposed grading system and prognosis in patients with invasive lung adenocarcinomas","volume":"178","author":"Fan","year":"2023","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.ejso.2024.108540_bib25","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00259-023-06434-7","article-title":"PET\/CT-based deep learning grading signature to optimize surgical decisions for clinical stage I invasive lung adenocarcinoma and biologic basis under its prediction: a multicenter study","volume":"51","author":"Zhong","year":"2024","journal-title":"Eur J Nucl Med Mol Imag"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798324005924?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798324005924?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T02:19:57Z","timestamp":1726798797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798324005924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0748798324005924"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2024.108540","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of extensive lymph node dissection in the new grading system for lung adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2024.108540","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108540"}}